AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trends

Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients receiving GLP-1 RA therapies.

Data from an 18-week, open-label Phase 3 study evaluated the safety and efficacy of up to three repeat treatments of TrenibotE for glabellar lines. According to the company, the investigational botulinum toxin type E demonstrated a consistent safety profile across treatment cycles, with no new safety concerns or development of neutralizing antibodies. Efficacy outcomes showed rapid reduction in glabellar line severity, with effects observed as early as 8 hours following administration and maintained across repeat treatments. TrenibotE is characterized by a shorter duration of effect, reported as approximately 2 to 3 weeks.

In a separate analysis, Allergan Aesthetics reported findings from a survey of US health care professionals examining patients treated with GLP-1 RA. The data indicated that this population is increasing across aesthetic practices, with an estimated 52% of patients expressing concern about facial appearance during treatment. Providers reported that 32% of these patients were new to their practice.

Barriers to aesthetic treatment in this group included cost (82%) and fear of unnatural results (58%). Survey respondents also described the patient population as predominantly female (70%), White (64%), and aged 30 to 49 years (56%).

Together, these findings reflect ongoing clinical development in neurotoxin therapies and evolving patient demographics within aesthetic dermatology.